Literature DB >> 10887148

Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis.

A Tefferi1, S Y Yoon, C Y Li.   

Abstract

Recent studies have shown decreased megakaryocyte expression of the thrombopoietin receptor (c-mpl) in patients with polycythemia vera (PV) but not in those with reactive erythrocytosis. We examined the diagnostic utility of this observation in 22 patients with PV, 7 patients with secondary erythrocytosis (SE), and 10 normal controls. Commercial antibodies against c-mpl were used with standard immunoperoxidase methods. Megakaryocyte c-mpl staining intensity was uniformly moderate-to-strong in the healthy controls and in all the patients with SE. In contrast, staining intensity in 9 patients with PV (41%) was uniformly weak. Furthermore, in 12 of the remaining 13 patients with PV, the c-mpl staining pattern in each case was heterogeneous and was associated with weak staining intensity in more than 20% of the megakaryocyte population. These preliminary data suggest that c-mpl immunostains may complement bone marrow histopathology in distinguishing PV from nonclonal causes of erythrocytosis. (Blood. 2000;96:771-772)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887148

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

Review 3.  A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).

Authors:  Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 4.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 5.  The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases.

Authors:  Chin-Yang Li
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 6.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.

Authors:  Caroline Marty; Ronan Chaligné; Catherine Lacout; Stefan N Constantinescu; William Vainchenker; Jean-Luc Villeval
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

Review 8.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.